| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
158.12(B) |
| Last
Volume: |
2,436,955 |
Avg
Vol: |
2,722,982 |
| 52
Week Range: |
$214.27 - $324.56 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 499 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
12,096 |
21,654 |
43,486 |
| Total Sell Value |
$0 |
$3,300,412 |
$5,808,718 |
$11,189,871 |
| Total People Sold |
0 |
2 |
3 |
6 |
| Total Sell Transactions |
0 |
2 |
3 |
9 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
• • – |
2023-03-17 |
4 |
D |
$234.57 |
$887,847 |
D/D |
(3,785) |
38,041 |
|
- |
|
| Miller Derek |
SVP, Human Resources |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
920 |
6,905 |
|
- |
|
| Gordon Murdo |
EVP Global Commercial Ops |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
7,947 |
55,621 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
687 |
7,338 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
7,753 |
65,676 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
968 |
14,032 |
|
- |
|
| Griffith Peter H. |
EVP & CFO |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
7,753 |
32,541 |
|
- |
|
| Louie Linda H. |
VP, Finance & CAO |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
387 |
9,679 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
27,915 |
648,712 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
7,947 |
56,167 |
|
- |
|
| Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
7,560 |
41,620 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2022-11-09 |
4 |
S |
$292.90 |
$113,352 |
D/D |
(387) |
6,630 |
|
20% |
|
| Drake Michael V |
Director |
• • – |
2022-11-08 |
4 |
A |
$0.00 |
$0 |
D/D |
171 |
810 |
|
- |
|
| Ishrak Omar |
Director |
• • – |
2022-11-08 |
4 |
A |
$0.00 |
$0 |
D/D |
222 |
2,302 |
|
- |
|
| Kullman Ellen Jamison |
Director |
• • – |
2022-11-08 |
4 |
A |
$0.00 |
$0 |
D/D |
222 |
10,113 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2022-11-08 |
4 |
S |
$293.54 |
$159,977 |
D/D |
(545) |
13,009 |
|
21% |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2022-11-05 |
4 |
D |
$269.04 |
$64,570 |
D/D |
(240) |
13,554 |
|
- |
|
| Miller Derek |
SVP, Human Resources |
• • – |
2022-11-05 |
4 |
D |
$269.04 |
$16,950 |
D/D |
(63) |
5,973 |
|
- |
|
| Louie Linda H. |
VP, Finance & CAO |
• • – |
2022-11-05 |
4 |
D |
$269.04 |
$12,107 |
D/D |
(45) |
9,278 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2022-11-05 |
4 |
D |
$269.04 |
$45,199 |
D/D |
(168) |
7,017 |
|
- |
|
| Louie Linda H. |
VP, Finance & CAO |
• • – |
2022-11-02 |
4 |
D |
$272.06 |
$34,008 |
D/D |
(125) |
9,323 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2022-11-02 |
4 |
D |
$272.06 |
$663,826 |
D/D |
(2,440) |
48,136 |
|
- |
|
| Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
• • – |
2022-11-01 |
4 |
D |
$270.35 |
$444,455 |
D/D |
(1,644) |
33,963 |
|
- |
|
| Griffith Peter H. |
EVP & CFO |
• • – |
2022-11-01 |
4 |
D |
$270.35 |
$819,161 |
D/D |
(3,030) |
24,675 |
|
- |
|
| Gordon Murdo |
EVP Global Commercial Ops |
• • – |
2022-08-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
400 |
47,484 |
|
- |
|
2150 Records found
|
|
Page 5 of 86 |
|
|
0.60 (0.22%) 
